Description of multiple myeloma cases and assessment of survival and mortality factors in Madagascar

References

• Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43(6):676–681. doi:10.1053/j.seminoncol.2016.11.004
   PubMed Web of Science ®Google Scholar
• The Global Cancer Observatory. Multiple myeloma – GLOBOCAN 2020. [fact-sheets], [accessed 2023 February 23]. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/35-Multiple-myeloma-fact-sheet.pdf
   Google Scholar
• The Global Cancer Observatory. United States of America – GLOBOCAN 2020 [fact-sheets]. [accessed 2023 February 23]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/840-united-states-of-america-fact-sheets.pdf
   Google Scholar
• The Global Cancer Observatory. France – GLOBOCAN 2020 [fact-sheets]. [accessed 2023 February 23]. Available at: https://gco.iarc.fr/today/data/factsheets/populations/250-france-fact-sheets.pdf
   Google Scholar
• Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519–527. doi:10.1016/S0140-6736(16)31594-X
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. doi:10.1182/blood-2007-10-116129
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(8):981–1114. doi:10.1002/ajh.25117
   PubMed Web of Science ®Google Scholar
• Andrianarison JFL, Ranoharison HD, Rakotoarivelo RA, et al. Myélome multiple chez les Malgaches. Hematologie. 2009;S1(15):74.
   Google Scholar
• Harioly Nirina MOM, Rasolonjatovo AS, Tsifanesy BG, et al. Description of 48 cases of multiple myeloma seen in the hematology laboratory of the CHU-Joseph Ravoahangy Andrianavalona, Antananarivo, Madagascar. Med Sante Trop. 2018;28(1):73–75. doi:10.1684/mst.2018.0763
   PubMed Web of Science ®Google Scholar
• Durie BGM, Salmon SE. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36(3):842–854. doi:10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u
   PubMed Web of Science ®Google Scholar
• Ranaivomanana AHM, Hasiniatsy NRE, Randriamalala NCR, et al. Epidemiology of cancers at the oncology department of the Joseph Ravoahangy Andrianavalona Teaching Hospital of Antananarivo from 2009 to 2010. Revue Malgache de Cancérologie. 2021;5(1):194–210.
   Google Scholar
• The Global Cancer Observatory. Madagascar – GLOBOCAN 2020 [fact-sheets]. [accessed février 2023 23]. Avalaible at: https://gco.iarc.fr/today/data/factsheets/populations/450-madagascar-fact-sheets.pdf
   Google Scholar
• Brahem M, Jguirim M, Klii R, et al. Myélome multiple : étude descriptive de 94 cas. Rev Med Interne. 2015;36(S2):A139–A140. doi:10.1016/j.revmed.2015.10.087
   Google Scholar
• Ngo Sack FF, Ngouadjeu E, Carre JL. Multiple myeloma epidemiological, clinical, paraclinical aspects: about 67 observations collected at the central hospital of Yaoundé and the general hospital of Douala. RAMReS Sciences de la Santé. 2017;5:2.
   Google Scholar
• Boufrioua EG, Mohammed O, Hicham Y, Mustapha AM, Chakour M. Le myélome multiple : les particularités diagnostiques, thérapeutiques et pronostiques de 123 cas colligés à l´Hôpital Militaire Avicenne de Marrakech. PAMJ Clin Med 2021; 5(70). doi:10.11604/pamj-cm.2021.5.70.20639
   Google Scholar
• Sverrisdóttir IS, Rögnvaldsson S, Thorsteinsdottir S, et al. Comorbidities in multiple myeloma and implications on survival: a population-based study. Eur J Haematol. 2021;106(6):774–782. doi:10.1111/ejh.13597
   PubMed Web of Science ®Google Scholar
• Turesson I, Bjorkholm M, Blimark CH, et al. Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival. Eur J Haematol. 2018;101(2):237–244. doi:10.1111/ejh.13083
   Web of Science ®Google Scholar
• Gregersen H, Vangsted AJ, Abildgaard N, et al. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study. Cancer Med. 2017;6(7):1807–1816. doi:10.1002/cam4.1128
   PubMed Web of Science ®Google Scholar
• Chari A, Mezzi K, Zhu S, et al. Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer. 2016;16(1):912, doi:10.1186/s12885-016-2955-0
   PubMedGoogle Scholar
• Backs D, Saglam I, Löffler C, et al. Prevalence of cardiovascular risk factors and diseases in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Oncotarget. 2019;10(34):3154–3165. doi:10.18632/oncotarget.26872
   PubMedGoogle Scholar
• La L, Jagannath S, Ailawadhi S, et al. Clinical features and survival outcomes in diabetic patients with newly diagnosed multiple myeloma (NDMM) enrolled in the Connect® MM registry. Blood. 2020;136(1):49–50. doi:10.1182/blood-2020-137309
   Google Scholar
• Manier S, Leleu X. Multiple myeloma: clinical diagnosis and prospect of treatment. Recommendations of the International Myeloma Working Group (IMWG). Immunoanal Biol Spe. 2011;26(3):125–136.
   Google Scholar
• Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016;34(13):1544–1557. doi:10.1200/JCO.2015.65.0044
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33. doi:10.4065/78.1.21
   PubMed Web of Science ®Google Scholar
• Moulopoulos LA, Koutoulidis V, Hillengass J, et al. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. Blood Cancer J. 2018;8(10):95, doi:10.1038/s41408-018-0124-1
   PubMedGoogle Scholar
• Kyle RA. Multiple myeloma: review of 869 cases. Mayo Clin Proc. 1975;50(1):29–40.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5
   PubMed Web of Science ®Google Scholar
• Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910–921. doi:10.3324/haematol.2016.162693
   PubMed Web of Science ®Google Scholar